PMID- 29350052
OWN - NLM
STAT- MEDLINE
DCOM- 20190107
LR  - 20240109
IS  - 1477-0903 (Electronic)
IS  - 0960-3271 (Linking)
VI  - 37
IP  - 10
DP  - 2018 Oct
TI  - Protective mechanisms of 6-gingerol in dextran sulfate sodium-induced chronic 
      ulcerative colitis in mice.
PG  - 1054-1068
LID - 10.1177/0960327117751235 [doi]
AB  - Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the 
      colon, with an increasing incidence worldwide. 6-Gingerol (6G) is a bioactive 
      constituent of Zingiber officinale, which has been reported to possess various 
      biological activities. This study was designed to evaluate the role of 6G in 
      chronic UC. Chronic UC was induced in mice by three cycles of 2.5% dextran 
      sulfate sodium (DSS) in drinking water. Each cycle consisted of 7 days of 2.5% 
      DSS followed by 14 days of normal drinking water. 6G (100 mg/kg) and a reference 
      anti-colitis drug sulfasalazine (SZ) (100 mg/kg) were orally administered daily 
      to the mice throughout exposure to three cycles of 2.5% DSS. Administration of 6G 
      and SZ significantly prevented disease activity index and aberrant crypt foci 
      formation in DSS-treated mice. Furthermore, 6G and SZ suppresses immunoexpression 
      of tumor necrosis factor alpha, interleukin-1beta, inducible nitric oxide synthase, 
      Regulated on activation, normal T cell expressed and secreted (RANTES), and 
      Monocyte chemoattractant protein-1 (MCP-1) in the DSS-treated mice. 6G 
      effectively protected against colonic oxidative damage by augmenting the 
      antioxidant status with marked decrease in lipid peroxidation levels in 
      DSS-treated mice. Moreover, 6G significantly inhibited nuclear factor kappa B 
      (P65), p38, cyclooxygenase-2, and beta-catenin whereas it enhanced IL-10 and 
      adenomatous polyposis coli expression in DSS-treated mice. In conclusion, 6G 
      prevented DSS-induced chronic UC via anti-inflammatory and antioxidative 
      mechanisms and preservation of the Wnt/beta-catenin signaling pathway.
FAU - Ajayi, B O
AU  - Ajayi BO
AD  - Department of Biochemistry, Drug Metabolism & Toxicology Research Laboratories, 
      College of Medicine, University of Ibadan, Ibadan, Nigeria.
FAU - Adedara, I A
AU  - Adedara IA
AD  - Department of Biochemistry, Drug Metabolism & Toxicology Research Laboratories, 
      College of Medicine, University of Ibadan, Ibadan, Nigeria.
FAU - Farombi, E O
AU  - Farombi EO
AD  - Department of Biochemistry, Drug Metabolism & Toxicology Research Laboratories, 
      College of Medicine, University of Ibadan, Ibadan, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20180119
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Catechols)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Fatty Alcohols)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (NF-kappa B)
RN  - 0 (beta Catenin)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 9042-14-2 (Dextran Sulfate)
RN  - 925QK2Z900 (gingerol)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Catechols/administration & dosage/*pharmacology
MH  - Chemokines/metabolism
MH  - Chronic Disease
MH  - Colitis, Ulcerative/chemically induced/metabolism/pathology/*prevention & control
MH  - Cytokines/metabolism
MH  - Dextran Sulfate
MH  - Fatty Alcohols/administration & dosage/*pharmacology
MH  - Gastrointestinal Agents/therapeutic use
MH  - Genes, APC
MH  - Zingiber officinale/*chemistry
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Mice, Inbred BALB C
MH  - NF-kappa B/antagonists & inhibitors
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Oxidative Stress/drug effects
MH  - Phenotype
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Sulfasalazine/therapeutic use
MH  - Wnt Signaling Pathway/drug effects
MH  - beta Catenin/antagonists & inhibitors
OTO - NOTNLM
OT  - 6-Gingerol
OT  - antioxidant
OT  - oxidative stress
OT  - ulcerative colitis
OT  - beta-catenin
EDAT- 2018/01/20 06:00
MHDA- 2019/01/08 06:00
CRDT- 2018/01/20 06:00
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2018/01/20 06:00 [entrez]
AID - 10.1177/0960327117751235 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 2018 Oct;37(10):1054-1068. doi: 10.1177/0960327117751235. Epub 
      2018 Jan 19.